selumetinib

FDA Drug Profile

Drug Details

Generic Name
selumetinib
Brand Names
N/A
Application Number
Sponsor
Patheon Pharmaceuticals Inc.
NDC Codes
2
Dosage Forms
CAPSULE
Routes
N/A
Active Ingredients
SELUMETINIB

Indications and Usage

1 INDICATIONS AND USAGE KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ]. KOSELUGO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )